Aditya Singh, Vaseem A. Ansari, Farogh Ahsan, Juber Akhtar, Poonam Khushwaha, Shubhrat Maheshwari, Rufaida
Aditya Singh1*, Vaseem A. Ansari1, Farogh Ahsan1, Juber Akhtar1, Poonam Khushwaha1, Shubhrat Maheshwari2*, Rufaida1
1Faculty of Pharmacy, Integral University, Lucknow India.
2Shri Ram Murti Smarak College of Engineering and Technology, Pharmacy Bareilly India.
Volume - 14,
Issue - 5,
Year - 2021
Cancer predicament is a global concern because of the ability of swift growth to cause infection to the cell. Breast cancer is the fifth contemplative reason for cancer death many scientific approaches have been thriving to deal with it and to make anticancer agent, therapeutic, safe and effective. In this burgeon silver was found as antitumor agent with noteworthy properties of conductivity, stability, and activity. Soy isoflavones mainly derived from soybean have accure much attention as dietary components having inhibitory effects on breast cancer and prostate cancer in Asians, who consume 20-50 times more than Americans, soy diet act as a natural chemopreventive agent. Previous data show that nanoparticles of silver are effective against a wide spectrum of bacteria, fungi, viruses, some infectious diseases and burn wounds. Now genistein has been found to inhibit the growth of various cancer cell lines including prostate and breast cancer cells. Nanoparticles needed to be biosynthesized because of the expensive, physical and. chemical processes. Chemical synthesis also contributes to the appearance on the surface of some toxic chemical that can adversely affect medical applications. Green synthesis offers advances over chemical and physical method because it is price effective, environmentally friendly, easily scaled up for large scale synthesis and does not requires use high pressure, energy, temperature and toxic chemicals.
Cite this article:
Aditya Singh, Vaseem A. Ansari, Farogh Ahsan, Juber Akhtar, Poonam Khushwaha, Shubhrat Maheshwari, Rufaida. Viridescent Concoction of Genstein Tendentious silver Nanoparticles for Breast Cancer. Research Journal of Pharmacy and Technology. 2021; 14(5):2867-2. doi: 10.52711/0974-360X.2021.00504
Aditya Singh, Vaseem A. Ansari, Farogh Ahsan, Juber Akhtar, Poonam Khushwaha, Shubhrat Maheshwari, Rufaida. Viridescent Concoction of Genstein Tendentious silver Nanoparticles for Breast Cancer. Research Journal of Pharmacy and Technology. 2021; 14(5):2867-2. doi: 10.52711/0974-360X.2021.00504 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-88
1. Transcript available at http://www.its.caltech.edu/-feynman/plenty.html 2009.
2. Committee for the review of National Nanotechnology Initiative, Division on Engineering and Physical Sciences, National Research Council, Small wonders, endless frontiers: A review of the National Nanotechnology Initiative, National Academy Press, Washington DC, 2002.
3. Hasan S, A Review on Nanoparticles: Their Synthesis and Types Biosynthesis: Mechanism 2005; 49-11.
4. Assessment R, Nanoparticles in the Environment 2007.
5. Osuwa JC, Anusionwu PC, Some advances and prospects in nanotechnology: a review, Asian J Inf Technol 2011; 10: 96-100.
6. Sriram MI, Kalishwaralal K, Barathmanikanth S, Gurunathani S. Size-based cytotoxicity of silver nanoparticles in bovine retinol endothelial cells, Nanosci Methods 2012; 1:56-77.
7. Zhu B, Li Y, Lin Z, et al. Silver Nanoparticles Induce hepg-2 Cell Apoptosis Through ROS-Mediated Signaling pathways. Nanoscale Res Lett, 2016; 11: 198.
8. Malik MA, O’Brien P, Revaprasadu N. A simple route to the synthesis of core/shell nanoparticles of chalcogenides, Chemistry of Materials 2004; 14-210.
9. Malik P, Shanskar, R, Malik, V, Sharma, N, and Mukherjee, T. K. Green chemistry based bengin routes for nanoparticles synthesis, J Nanopar, Article ID 302429 (2014).
10. Gan, P.P., Ng, S.H., Huang, Y. and Li, S. F, Green synthesis of gold nanoparticles using palm oil mill effluent (POME): a low-cost and eco-friendly viable approach. Bioresour Technol 2012; 132-135.
11. Zoonoz, N. F. and Salouti, M. Extracellular biosynthesis of silver nanoparticles using cell filterate of Streptomyces sp. ERI-3. Sci Iran, 2011; 1631-5.
12. Gilaki, M. Biosynthesis of silver nanoparticles using plant extracts. J Biol Sci 10, 2010; 465-467.
13. EI-Naggar, N. E., Mohamedin, A., Hamza, S. S. and Sherief, A.-D. Extracellular biofabrication, characterization, and antimicrobial efficacy of silver nanopaticles loaded on cotton fabrics using newly isolated Streptomyces sp. SSHH-1E. J Nanomate, ID 3257359 (2016).
14. Saifuddin, N, Wong, C. W. and Nur Yasumira, A. A. Rapid biosynthesis of silver nanoparticles using culture supernatant of bacteria with microwave irradiation, J Chem 2009; 661-70.
15. Okitsu, K., Mizukoshi, Y., Yamamoto, T. A., Maeda, Y. and Nagata, Y. Sonochemical synthesis of gold nanoparticles on chitosan, Mater Lett, 2007; 3429-3431.
16. EL-Sheekh, M.M. and El-Kassa, H. Y. Algal production of nano-silver and gold: Their antimicrobial and cytotoxic activities: a review. Genet Eng Biotechnol, 2016; 299-310.
17. Chan K, Morris GJ, Chemoprevention of breast cancer for women at high risk, In: Seminars in oncology, Elsevier, 2006; 642-646.
18. Jemal A, Thomas A, Murray T, Thun M, Cancer statistics, CA: a cancer journal for clinicians, 2002; 52:23-47.
19. Johnston SR, Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications, Anti-cancer drugs, 1997; 8:911-930.
20. Fong J, Wood F, Nanocrystalline silver dressings in wound management: a review, International Journal of Nanomedicine, 2006; 1:441.
21. Sriram MI, Kanth SBM, Kalishwaralal K, Gurunathan S, Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model, Int J Nanomedicine, 2010; 5: 753-762.
22. Sun Y, Yin Y, Mayers BT, Herricks T, Xia Y et al, Uniform silver nanowires synthesis by reducing AgNO3 with ethylene glycol in the presence of seeds and poly (vinyl pyrrolidone), Chemistry of Materials 2002;14: 4736-4745.
23. Johnston SR, Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications, Anti-cancer drugs, 1997; 8: 911-930.
24. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, et al. (1996) The significance ofheregulin in breast cancer tumor progression and drug resistance. Breast cancer research and treatment, 1996; 38: 57-66.
25. Brown K, Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen, Expert opinion on drug safety, 2002; 1: 253-267.
26. Smith LL, Brown K, Carthew P, Lim C-K, Martin EA, et al. Chemoprevention of breast cancer by tamoxifen: risks and opportunities, Critical reviews in toxicology, 2000; 30: 571-594.
27. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, et al, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, Journal of Clinical Oncology, 2008; 26: 4282-4288.
28. American Cancer Society, How Common Is Breast Cancer. Available at: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html, 2020.
29. American Cancer Society, Cancer Facts and Figures. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statics/annual-cancer-facts-and-figures-2020.pdf 2020.
30. National Cancer Institute, BRCA Mutations: Cancer Risk and Genetic Testing, Available at: https://www.cancer.govt/about-cancer/causes-prevention/genetics/brca-fact-sheet, 2018.
31. Adlercreutz, C. H, Goldin, B. R, Gorbach, S. L, Hockerstedt, K. A, Watanabe, S, Hamalainen, E. K, Markkanen, M. H, Makela, T. H.; Wahala, K. T, Adlercreutz, T. J. Nutr, 1995;125- 757.
32. Hebert, J. R, Hurley, T. G, Olendzki, B. C, Teas, J, Ma, Y, Hampl, J. S. J. Natl, Cancer Inst, 1998; 90-1637.
33. Jacobsen, B. K, Knutsen, S. F, Fraser, G. E, Cancer Causes Control, 1998; 9-553.
34. Lee, H. P, Gourley, L, Duffy, S. W, Esteve, J, Lee, J, Day, N. E. Lancet, 1991; 337-1197.
35. Adlercreutz, H, Honjo, H, Higashi, A, Fotsis, T, Hamalainen, E, Hasegawa, T, Okada, H. Am. J. Clin. Nutr, 1991; 54-1093.
36. Adlercreutz, H, Fotsis T, Lampe J, Wahala, K, Makela, T, Brunow, G, Hase, T, Scand. J, Clin Lab. Invest Suppl, 1993; 215-5.
37. King, R. A, Bursill, D. B. Am. J. Clin. Nutr, 1998; 67-867.
38. Morton, M. S, Wilcox, G, Wahlqvist, M. L, Griffiths, K. J. Endocrinol, 1994;142-251.
39. Rannikko, A, Petas, A, Rannikko, S, Adlercreutz, H. Prostate, 2005.
40. Adlercreutz, H, Fotsis, T, Watanabe, S, Lampe, J.; Wahala, K.; Makela, T.; Hase, T. Cancer Detect. Prev, 1994; 18-259.
41. Barnes, S. J, Nutr, 1995; 125; 777.
42. Li, Y.; Upadhyay, S.; Bhuiyan, M.; Sarkar, F. H. Oncogene, 1999; 18-3166.
43. Gurunathan S, Raman J, Malek SNA, John PA, Vikineswary S. Green synthesis of silver nanoparticles using Ganderma neo-japnicum Imazeki: a potential cytotoxic agent against breast cancer cells, Int J Nanomedicine 2013; 8: 4399-4413.
44. Nazir S, Hussain T, Iqbal Md, Mazhar K, Muazzam AG, Ismail J Md. Novel and cost effective green synthesis of silver nanoparticles and their in vivo antitumor properties against human cancer cell lines, Biosci Tech 2011; 2: 425-443.
45. Jacob SJP, Finub JS, Narayanan A. Synthesis of silver nanoparticles using piper longum leaf extracts and its cytotoxic activity against Hep2 cell line, Colloids Surf B Biointerfaces 2012; 91: 212-214.
46. Govindaraju K, Krishnamoorthy K, Alsagaby SA, Singaravelu G, Premanathan M, Green synthesis of silver nanoparticles for selective toxicity towards cancer cells, IET Nanobiotechnol, 2015; 9: 325-330.
47. Oh KH, Soshnikova V, Markus J, et al., Biosynthesized gold and silver nanoparticles by aqueous fruit extract of Chaenomeles sinesis and screening of biomedical activities, Artif Cells Nanomed Biotechnol, 2018; 46: 599-606.
48. Walter, E. D. Genistin (an Isoflavone Glucoside) and its Aglucone, Genistein, from Soybeans. Journal of the American Chemical Society, 1941; 63 (12):3273–76.
49. Rao, H. S. P.; Reddy, K. S. "Isoflavones from Flemingia vestita". Fitoterapia, 1991; 62 (5): 458.
50. Gossner, G; Choi, M; Tan, L; Fogoros, S; Griffith, K; Kuenker, M; Liu J, "Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells". Gynecologic Oncology, 2007; 105 (1): 23–30.
51. Zhang J, Cheng F, Zheng T, Zhu J, Versatile aptasensor for electrochemical quantification of cell surface glycan and naked-eye tracking glycolytic inhibition in living cells, Biosens Bioelectron, 2017;89:937–945.
52. Zhang J, Gu M, Zheng T, Zhu J, Synthesis of Gelatin-stabilized gold nanoparticles and assembly of carboxylic single-walled carbon nanotubes/Au composites for cytosensing and drug uptake. Anal Chem, 2009; 81:6641–6664.
53. Yu D-G, Formation of colloidal silver nanoparticles stabilized by Na+–poly (γ-glutamic acid)–silver nitrate complex via chemical reduction process, Colloids Surf B, 2007;59(2):171–178.
54. Bray F, Ferlay J, Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin, 2018; 68:394–424.
55. Vickers A, Alternative cancer cures: “Unproven” or “disproven”? CA A Cancer J. Clin, 2004; 54:110–118.
56. Wang M, Thanou M, Targeting nanoparticles to cancer Pharmacol Res, 2010; 62:90–99.
57. Chouhan N, Silver Nanoparticles-Fabrication, Characterization and Applications, Silver nanoparticles: Synthesis, characterization and applications;. Intech Open; London, 2018; 21–57.
58. Nguyen K.T, Targeted nanoparticles for cancer therapy: Promises and challenge, Nanomed. Nanotechnol, 2011.
59. Li X., Cui R., Liu W., Sun L., Yu B., Fan Y., Feng Q., Cui F., Watari F. The use of nanoscaled fibers or tubes to improve biocompatibility and bioactivity of biomedical materials. J. Nanomater, 2013.
60. Russell A., Hugo W. 7 antimicrobial activity and action of silver, Prog, Med. Chem, 1994; 31:351–370.
61. Lee S.H., Jun B.H, Silver nanoparticles: Synthesis and application for nanomedicine. Int. J. Mol. Sci, 2019.
62. Chen X, Schluesener H.J, Nanosilver: A nanoproduct in medical application, Toxicol. Lett, 2008; 176:1–12.